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Glycolytic enzymes are attractive anticancer targets.
They also carry out numerous, nonglycolytic ‘‘moon-
lighting’’ functions in cells. In this study, we investi-
gated the anticancer activity of the triazine small
molecule, GAPDS, that targets the glycolytic en-
zyme glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). GAPDS showed greater toxicity against
cancer cells compared to a known GAPDH enzyme
inhibitor. GAPDS also selectively inhibited cell migra-
tion and invasion. Our analysis showed that GAPDS
treatment reduced GAPDH levels in the cytoplasm,
which would modulate the secondary, moonlighting
functions of this enzyme. We then used GAPDS as
a probe to demonstrate that a moonlighting function
of GAPDH is tubulin regulation, which may explain
its anti-invasive properties. We also observed that
GAPDS has potent anticancer activity in vivo. Our
study indicates that strategies to target the second-
ary functions of anticancer candidates may yield
potent therapeutics and useful chemical probes.
INTRODUCTION
Glycolysis is the breakdown of glucose into pyruvate to generate
ATP. It is an ancient, highly conserved metabolic pathway that
developed under anaerobic conditions, i.e., before the appear-
ance of significant levels of photosynthesis-derived oxygen in
the atmosphere (Kim and Dang, 2005). Increased glycolysis is
a hallmark of cancer cells and is known as the Warburg effect
(Warburg et al., 1927). For example, the rate of glycolysis in
homogenized tumor tissues is approximately ten times that of
normal tissues, which has led to the description of cancer cells
as ‘‘glycolysis addicts’’ (Bagley, 2010). The Warburg effect isChemistry & Biology 21, 1533–154thought to be a metabolic adaptation to hypoxia that arises
during tumorigenesis (Kim and Dang, 2005). This offers a thera-
peutic strategy to selectively kill cancer cells using glycolysis
inhibitors, which can overcome drug resistance to induce cell
death (Xu et al., 2005).
The individual enzymes constituting the glycolysis pathway
were thought of as ‘‘ancient’’ or ‘‘boring’’ proteins with well-
characterized catalytic functions and structural properties (Kim
and Dang, 2005). However, over the past decade, this view
has been revised, and many glycolytic enzymes are now classi-
fied as ‘‘moonlighting’’ proteins (Jeffery, 2009). These proteins
carry out additional functions that are unrelated to their originally
characterized biological activity. Many examples of moon-
lighting by glycolytic enzymes have been discovered. Some
are related to carcinogenesis. For example, glyceraldehyde
3-phosphate dehydrogenase (GAPDH) can translocate to the
cell nucleus, where it has a role in the regulation of apoptosis.
This has been linked to the promotion of tumorigenesis (Colell
et al., 2009). Onemechanism by which nuclear localized GAPDH
regulates cell death is via complex formation with promyelocytic
leukemia protein (Tristan et al., 2011). Moreover, GAPDH can act
as a prosurvival factor by stimulating autophagy-mediated clear-
ance of permeabilized mitochondria (Tristan et al., 2011). Exam-
ples of moonlighting by other glycolytic enzymes include lactate
dehydrogenase, which was identified as a regulator of gene tran-
scription via association with the Oct-1 coactivator in S-phase
(OCA-S) transcription complex (Dai et al., 2008), and enolase,
which can be alternatively spliced to regulate transcription of
the oncogene, Myc (Subramanian and Miller, 2000).
The triazine-based small molecule, GAPDH segregator
(GAPDS), targets GAPDH and was first described in 2007 (Min
et al., 2007). GAPDS treatment produced antidiabetic effects in
the roundworm,Caenorhabditis elegans, andmammalian adipo-
cytes, which demonstrated that GAPDH is a candidate for
diabetes drug discovery. In cells, GAPDH forms a tetramer for
full enzyme activity. GAPDS binding dissociates the GAPDH
tetramer into monomers (Min et al., 2007). GAPDH is upregu-
lated in different cancers and has been linked to numerous5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1533
Figure 1. GAPDS Inhibits GAPDH Activity
and Reduces Cancer Cell Viability
(A) Effects of GAPDS, 6-OHDA, and iodoaceta-
mide on GAPDH activity in human HCT116 colon
carcinoma cells. Cells were incubated with in-
hibitors for 24 hr. Error bars indicate SD; *p < 0.05
compared to untreated cancer cells. A photograph
of the assay plate is included.
(B) Effect of GAPDS, 6-OHDA, and iodoacetamide
on ATP levels in human HCT116 colon carcinoma
cells. Cells were incubated with inhibitors for 24 hr,
and ATP content was measured using a lumines-
cence-based assay. Error bars indicate SD; *p <
0.05 compared to untreated cancer cells.
(C) Effect of GAPDS or 6-OHDA treatment on
HCT116 human colon carcinoma cell viability
under normoxia and hypoxia. Cells were treated
with compound for 48 hr. Error bars indicate SD;
*p < 0.05 compared to 6-OHDA-treated cancer
cells in the same experimental group.
(D and E) Cell death assay for HCT116 human
colon carcinoma cells treated with GAPDS or
6-OHDA under normoxia (D) or hypoxia (E). Cells
were treated with the compound of interest for
48 hr. Error bars indicate SD; *p < 0.05 compared
to untreated cancer cells.
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some diabetes drugs, such as metformin, are effective against
cancer (Gallagher and LeRoith, 2011). Therefore, we assessed
the anticancer properties of GAPDS, using cell-based assays,
biochemical analyses, and animal models. Our results indicate
that GAPDS is a potent anticancer agent that inhibits both the
primary and secondary functions of GAPDH. Moreover, our find-
ings demonstrate that GAPDS is an effective chemical probe for
studying GAPDH moonlighting.
RESULTS
GAPDS Inhibits GAPDH Activity and Reduces ATP Level
in Cancer Cells
The chemical structures of compounds used in this study
are shown in Figure S1 (available online). As our first analysis,
we measured the effect of GAPDS treatment on GAPDH
activity, ATP levels, and cell viability in HCT116 human colon
cancer cells (Figures 1A–1E). GAPDS was compared with the
known GAPDH inhibitors, iodoacetamide and 6-hydroxydop-
amine (6-OHDA) (Hayes and Tipton, 2002; Schmidt and
Dringen, 2009). We analyzed GAPDH activity and ATP levels1534 Chemistry & Biology 21, 1533–1545, November 20, 2014 ª2014 Elsevier Ltd All rights reat 24 hr treatment and cell viability at
48 hr treatment. These time points
were chosen because the effects of
GAPDH inhibitors may be influenced by
the induction of cell death. For example,
the nuclear localization of GAPDH and
reduced GAPDH activity occurs during
apoptosis (Fuchs et al., 2004; Ishitani
et al., 1998). In addition, ATP levels are
linked to the apoptotic process (Eguchi
et al., 1997).The previous report of GAPDS treatment in adipocytes used a
concentration of 10 mM (Min et al., 2007). We observed that
GAPDS inhibits GAPDH activity in HCT116 cells at a 10 mM treat-
ment concentration and this inhibition increases up to a treatment
concentration of 100 mM (Figure 1A). At these concentrations, the
inhibition of GAPDH activity by GAPDS was greater than the inhi-
bition produced by iodoacetamide treatment, but less than the in-
hibition produced by 6-OHDA. This difference between GAPDS
and iodoacetamide treatment was also observed in ATP levels
(Figure1B).GAPDS, iodoacetamideand6-OHDAtreatment signif-
icantly reduced cellular ATP, but GAPDS and 6-OHDA produced
a significantly greater reduction compared to iodoacetamide.
Therefore, for our subsequent analyses in cells, we compared
GAPDS with the more potent GAPDH inhibitor, 6-OHDA.
Compound GAPDS Induces Cancer Cell Death
To assess the effect of GAPDS on cancer cell viability in nor-
moxic and hypoxic conditions, we induced hypoxia pharmaco-
logically by exposure to cobalt chloride (Wu and Yotnda,
2011). Glycolysis inhibitors show greater effectiveness under
hypoxic conditions (Pelicano et al., 2006). We observed that
treatment with GAPDS produced a greater reduction in cellserved
Figure 2. GAPDS Treatment Reduces Cell
Viability in Different Cancer Cell Types
(A) Effect of GAPDS or 6-OHDA treatment onHT29
human colon carcinoma cell viability. Cells were
treated with compound for 48 hr. Error bars indi-
cate SD; *p < 0.05, compared to 6-OHDA-treated
cancer cells in the same experimental group.
(B) Cell death assay for HT29 cells treated with
GAPDS or 6-OHDA under normoxia. Cells were
treated with compound for 48 hr. Error bars indi-
cate SD; *p < 0.05, compared to 6-OHDA-treated
cancer cells in the same experimental group.
(C) Effect of GAPDS or 6-OHDA treatment on HeLa
human cervical carcinoma cell viability. Cells were
treated with compound for 48 hr. Error bars indi-
cate SD; *p < 0.05, compared to 6-OHDA-treated
cancer cells in the same experimental group.
(D) Cell death assay for HeLa cells treated with
GAPDS or 6-OHDA under normoxia. Cells were
treated with compound for 48 hr. Error bars indi-
cate SD; *p < 0.05, compared to 6-OHDA-treated
cancer cells in the same experimental group.
(E) Effect of GAPDS or 6-OHDA treatment on
HCT116 cell viability under hypoxia induced by
treatment with 500 mM deferoxamine mesylate for
16 hr. Cells were then treated with compound for
48 hr. Error bars indicate SD; *p < 0.05, compared
to 6-OHDA-treated cancer cells in the same
experimental group.
(F) Cell death assay for HCT116 cells treated with
GAPDS or 6-OHDA under hypoxia induced by
deferoxamine mesylate. Cells were treated with
compound of interest for 48 hr. Error bars indicate
SD; *p < 0.05, compared to untreated cancer cells.
(G) Effect of GAPDS or 6-OHDA treatment on
HCT116 human colon carcinoma cell viability un-
der hypoxia induced by treatment with 50 mM2,20-
dipyridyl for 18 hr. Cells were then treated with
compound for 48 hr. Error bars indicate SD; *p <
0.05, compared to 6-OHDA-treated cancer cells in
the same experimental group.
(H) Cell death assay for HCT116 cells treated with
GAPDS or 6-OHDA under hypoxia induced by
2,20-dipyridyl. Cells were treated with the com-
pound of interest for 48 hr. Error bars indicate SD;
*p < 0.05, compared to untreated cancer cells.
Chemistry & Biology
GAPDH Moonlighting Enhances Anticancer Activityviability compared to 6-OHDA (Figure 1C). This finding was
observed under both normoxia and hypoxia. However, cells
were more resistant under hypoxia. Therefore, to ascertain if
GAPDS treatment induced cell death under hypoxia, rather
than inhibiting proliferation, we measured trypan blue exclusion.
GAPDS treatment significantly increased cell death in HCT116
cells under normoxia and hypoxia compared to 6-OHDA (Figures
1D–1E). To confirm that GAPDS shows greater activity against
cancer cells than 6-OHDA, we tested two other cancer cell
types: a second human colon carcinoma cell line (HT29) and hu-
man cervical carcinoma (HeLa). We found that GAPDS treatment
produced a greater reduction in HT29 and HeLa viability
compared to 6-OHDA (Figures 2A–2D). The effect of GAPDS
and 6-OHDA on cells under hypoxia was confirmed using two
additional methods for hypoxic induction: treatment with defer-
oxamine mesylate (Yang et al., 2009) or with 2,20-dipyridylChemistry & Biology 21, 1533–154(Kuphal et al., 2013). Similar to themethod usedwith cobalt chlo-
ride, both methods are also based onmodifying the levels of free
iron. It was observed that GAPDS retained its greater effective-
ness at reducing cell viability compared to 6-OHDA (Figures
2E–2H). To characterize howGAPDS exerts its anticancer effect,
we used flow cytometric analysis of cell cycle status (Figure S2).
It was observed that GAPDS treatment under normoxia
increased the proportion of HCT116 cells in the G2/M phase,
indicating that cell proliferation became blocked at this stage
of the cell cycle. A similar effect was observed when cells were
treated with 6-OHDA (Figure S2).
GAPDS Induces GAPDH Degradation and
Downregulates Tubulin Expression in Cells
To further characterize the effect of GAPDS treatment in HCT116
cells, we measured the expression of GAPDH and markers of5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1535
Figure 3. GAPDS Induces the Expression of Apoptosis Markers and Reduces Tubulin Expression in Cancer Cells
(A) Western blot analysis of cleaved PARP, full-length PARP, cleaved caspase-9, full-length caspase, GAPDH, a-tubulin, and actin in HCT116 human colon
carcinoma cells after 48 hr compound treatment.
(B) Densitometry analysis shows average change in band intensity for three western blots (error bars indicate SD; *p < 0.05 for altered expression, compared to
untreated cells). Actin was used for normalization of protein loading. Western blots for GAPDH and a-tubulin in GAPDS-treated cells were four experimental
repeats.
(legend continued on next page)
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GAPDH Moonlighting Enhances Anticancer Activityapoptosis using western blot analysis (Figures 3A and 3B). The
apoptosis marker, cleaved enzyme poly (ADP-ribose) polymer-
ase (PARP) (Tewari et al., 1995), did not show any change in
expression in GAPDS-treated cells under normoxia. However,
the induction of hypoxia produced an increase in cleaved
PARP after GAPDS treatment. We observed that treatment
with 6-OHDA also produced an increase in PARP under hypoxia,
but not normoxia. Expression of the apoptosis marker, cleaved
caspase-9 (Li et al., 1997), also increased in GAPDS-treated
cells under hypoxia, but not normoxia (Figures 3A and 3B). In
contrast, there was no increase in cleaved caspase-9 expression
in cells treated with 6-OHDA.
Interestingly, we observed that GAPDH expression decreased
in HCT116 cells treated with GAPDS (Figures 3A and 3B). More-
over, 6-OHDA treatment did not affect GAPDH expression. The
ability of GAPDS to reduce the expression of GAPDH appeared
to be specific for this glycolytic enzyme, because GAPDS-
treated cells showed no reduction in the expression of the down-
stream glycolytic enzyme, enolase (Figure S3). Furthermore,
GAPDS treatment under normoxia also reduced the expression
of tubulin (Figures 3A and 3B).
To assess whether the reduction in GAPDH protein levels after
GAPDS treatment is caused by decreased protein expression,
we carried out RT-PCR analysis of GAPDH mRNA expression
(Figure 3C). It was observed that GAPDH messenger RNA
(mRNA) expression stayed constant after treatment with GAPDS
or 6-OHDA. GAPDH is known to undergo nuclear localization in
response to various stimuli. Therefore, we assessed the effect
of GAPDS treatment on nuclear levels of GAPDH (Figures 3D
and 3E). It was observed that treatment with GAPDS, but
not 6-OHDA, significantly increased the nuclear localization of
GAPDH.
GAPDS Blocks Cell Migration and Induces Cytoskeletal
Modification
In consequence of the finding that GAPDS treatment induces
tubulin downregulation, we assessed the effect of this com-
pound on cell motility. As a first test, we measured HCT116
cell invasion after treatment with GAPDS or 6-OHDA. It was
observed that GAPDS treatment reduced invasion, whereas
treatment with 6-OHDA had no effect (Figures 4A and 4B). This
difference between the two compounds could be observed at
a 10 mM treatment concentration, compared to the 50 mM treat-
ment concentration used to inhibit cell viability (Figure 1C). To
confirm that the effect of GAPDS on invasion is not restricted
to one cancer cell line, we measured invasion in MBA-MD-231
human breast carcinoma cells. It was observed that treatment
with GAPDS, but not 6-OHDA, also inhibited invasion in these
cells (Figures 4C and 4D). To visualize migrating cells after com-
pound treatment, we carried out the wound healing assay. It was
observed that GAPDS reduced cell motility, whereas 6-OHDA
treatment produced no significant effect (Figures 4E and S4).
The morphology of compound-treated cells was assessed by(C) RT-PCR analysis of GAPDH mRNA expression after 48 hr treatment with
normalization of the RT-PCR reaction. The numbers in red below each band sho
(D) Western blot analysis of nuclear localized GAPDH in HCT116 cells after treat
(E) Densitometry analysis shows average change in band intensity for three weste
untreated cells). Laminin was used for normalization of protein loading.
Chemistry & Biology 21, 1533–154light microscopy, which indicated that GAPDS-treated cells did
not form pseudopodia at the cell membrane (Figure S4).
Similarly tocompoundGAPDS, it isknown thatO-GlcNAcylation
alsodisrupts theGAPDH tetramerand inducesnuclear localization
(Park et al., 2009). Therefore, we induced O-GlcNAcylation of
cellular proteins using two methods; treatment with O-(2-acet-
amido-2-deoxy-D-glucopyranosylidene)amino N-phenyl carba-
mate (PUGNAc) or glucosamine (Champattanachai et al., 2007;
Haltiwanger et al., 1998). This would test if the effect of
GAPDS on GAPDH quaternary structure is responsible for the
inhibition of cell motility and invasion. It was observed that
treatment with glucosamine, but not PUGNAc, inhibited HCT116
cell invasion (Figures 4F and 4G). As a positive control, we used
the compound LY294002, which inhibits cell invasion by blocking
the phosphatidylinositol 3-kinase (PI3K) signaling pathway. To
confirm the effect of glucosamine on cell motility, we carried out
the wound healing assay. It was observed that treatment with
glucosamine inhibited cell motility in the wound healing assay
(Figure 4H).
In consequence of these results, we checked the status of the
cytoskeleton in GAPDS-treated HCT116 cells using Texas Red-
labeled phalloidin, which binds to actin. It was observed that
GAPDS treatment prevented actin polymerization at the leading
edge of the cell membrane (Figure 5A). We also assessed the
effect of PUGNAc or glucosamine treatment (Figure 5B). It was
observed that treatment with glucosamine, but not PUGNAc,
prevented actin polymerization at the leading edge of the cell
membrane.
Because of our finding that GAPDS treatment disrupts cell
motility, we tested cell viability after combined treatment with
another anticancer drug that targets the cytoskeleton. The
drug, Taxol, was chosen for this experiment because it is a
relatively well-characterized and widely used anticancer agent
(Cragg, 1998). It was observed that treatment with both
GAPDS and Taxol produced a synergistic effect on cell viability
(Figure 5C).
GAPDH Regulates Tubulin Expression in Cancer Cells
Our data indicated that GAPDS-treated HCT116 cells showed
decreased levels of GAPDH and tubulin expression (Figures
3A and 3B). Previous research has shown that GAPDH
interacts with the cytoskeleton and regulates microtubule poly-
merization (Andrade et al., 2004). This relationship between
GAPDH and tubulin expression was confirmed using small
interfering RNA (siRNA)-mediated knockdown of GAPDH ex-
pression (Figures 5D–5G). Reduced GAPDH activity after siRNA
treatment was detected using the KDalert GAPDH Assay Kit
(Invitrogen), which has been designed to optimize GAPDH
siRNA treatment (Figure 5E). In addition, knockdown of GAPDH
expression after siRNA treatment was detected by western
blot analysis (Figure 5G). It was observed that GAPDH gene
knockdown produced a reduction in tubulin expression (Figures
5D and 5F).GAPDS or 6-OHDA under normoxia or hypoxia. Cyclophilin was used for
w densitometric analysis of PCR product intensity.
ed with 100 mM 6-OHDA or GAPDS for 48 hr.
rn blots (error bars indicate SD; *p < 0.05 for altered expression, compared to
5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1537
Figure 4. GAPDS Inhibits Cancer Cell Migration and Invasion
(A) HCT116 human colon carcinoma invasion after treatment with GAPDS or 6-OHDA. Error bars indicate SD; *p < 0.05, compared to untreated cells.
(B) Representative image of transwells stained with crystal violet to visualize invaded cells.
(C) MBA-MD-231 human breast adenocarcinoma cell invasion after treatment with GAPDS or 6-OHDA. Error bars indicate SD; *p < 0.05, compared to untreated
cells.
(D) Representative images of invaded cancer cells stained with crystal violet. Scale bar, 100 mm.
(E) Quantification of wound healing by HCT116 cells after treatment with GAPDS or 6-OHDA. Error bars indicate SD; *p < 0.05, compared to 6-OHDA-treated
cells.
(F) HCT116 cell invasion after treatment with GAPDS, PUGNAc, glucosamine, or LY294002. Error bars indicate SD; *p < 0.05, compared to untreated cells.
(G) Representative images of invaded cancer cells stained with crystal violet. Scale bar, 50 mm.
(H) Quantification of wound healing byHCT116 cells after treatment with glucosamine or LY294002. Error bars indicate SD; *p < 0.05, compared to untreated cells.
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GAPDH Moonlighting Enhances Anticancer ActivityGAPDS Shows Effective Anticancer Activity In Vivo
To make an assessment of the anticancer effect of GAPDS
in vivo, we selected the zebrafish (Danio rerio) human tumor
xenograft model, which has become established as a system
for testing the effect of drug candidates on cancer cell migration
in host tissues (Jung et al., 2012; Konantz et al., 2012). This assay
also provides a vertebrate platform for predicting toxicological
effects in humans (Lee et al., 2013; Sipes et al., 2011). It was
observed that GAPDS-treated embryos remained viable and
showed normal developmental ‘‘landmarks’’ (Figure S5).
Using this model, we observed that GAPDS treatment blocked
human HCT116 cell dissemination and invasion in vivo (Fig-
ure 6A). Xenografted cancer cells remained restricted at the
transplantation site. In contrast, it was observed that treatment
with 6-OHDA did not block the dissemination of xenografted
cells, which retained their metastatic potential and could be visu-
alized throughout the host body. This difference in the anticancer
activity of GAPDS and 6-OHDA was confirmed by quantifying
cell dissemination (Figure 6B).
To validate that GAPDS is effective inmammals, we tested this
compound in a mouse syngeneic subcutaneous tumor model
(Figure S5) (Darro et al., 2005). Tumor progression was assessed
by in vivo imaging 10 days after transplantation of syngeneic
CT26 colon cancer cells, and it was observed that one out of
five mice developed a detectable tumor in the GAPDS-treated
group, compared to four out of five mice in the 6-OHDA- or
saline-treated groups. At 17 days posttransplantation, mice
were sacrificed, and tumors were excised from 6-OHDA-treated
mice were found to be smaller than tumors in the untreatedmice.
For the GAPDS-treated mice, it was observed that one tumor
was of a size similar to tumors in the untreated group. However,
three tumors were in the same size range as those in 6-OHDA-
treated mice, and one GAPDS-treated mouse had no detectable
subcutaneous tumor formation. Analysis of liver and spleen
weight indicated that GAPDS or 6-OHDA treatment had no effect
on liver mass. However, it was observed that 6-OHDA treatment
induced a significant decrease in spleen mass (Figure S5).
DISCUSSION
Glycolytic enzymes are attractive targets for cancer drug devel-
opment. In this study, our results show that the GAPDH targeting
triazine, GAPDS, is a potent anticancer compound that reduces
cytoplasmic levels of GAPDH, leading to reduced cancer cell
motility and decreased levels of tubulin.
We observed that GAPDS reduced cancer cell viability at a
treatment concentration of 50 mM and cell invasion at a concen-
tration of 10 mM (Figures 1 and 4). This compares favorably with
other known glycolysis inhibitors that target cancer cells. For
example, the glycolysis inhibitor 3-BrPa, which inhibits hexoki-
nase, is used in the 100–300 mM concentration range, and 2-de-
oxyglucose is used in the millimolar concentration range (Xu
et al., 2005; Zhang et al., 2006).
Our western blot analysis showed that increased expression
of the apoptosis marker cleaved PARP occurred in GAPDS- or
6-OHDA-treated cells, while expression of the apoptosis marker
cleaved caspase-9 could only be detected in GAPDS-treated
cancer cells (Figure 3). This finding suggests that there are differ-
ences in the mechanism by which these compounds induce cellChemistry & Biology 21, 1533–154death. For example, there are instances where apoptosis pro-
ceeds with PARP cleavage independently of caspase-9 cleav-
age, such as UV-induced apoptosis in breast adenocarcinoma
cell (Ferguson et al., 2003). Characterizing this potential differ-
ence in the induction of apoptosis could be an avenue for further
investigation. The ability of GAPDS to induce cancer cell death
under hypoxia is also of interest, because the hypoxic environ-
ment is known to favor the survival of cancer stem cells and
render other cancer drugs less effective (Xu et al., 2005). More-
over, the HCT116 cell line used in our study also possesses can-
cer stem cell qualities (Yeung et al., 2010). To induce hypoxia, we
used chemical treatment with cobalt chloride, which has been
validated in previous studies (Wu and Yotnda, 2011; Yuan
et al., 2003). We chose this method because it allows the exper-
imenter to open the culture dish without affecting the hypoxic
condition, which is suitable for testing candidate compounds
(Wu and Yotnda, 2011). However, to confirm our results that
GAPDS is effective against cancer cells, we used two additional
methods for producing hypoxia: treatment with deferoxamine
mesylate or treatment with 2,20-dipyridyl (Figures 2E–2H) (Ku-
phal et al., 2013; Martens et al., 2007; Spinella et al., 2010;
Yang et al., 2009).
We observed that GAPDS treatment markedly reduced
GAPDH levels in the cytoplasm of cancer cells (Figure 3A). The
specificity of this effect was signified by the finding that GAPDS
treatment did not affect the expression of the downstream glyco-
lytic enzyme, enolase. A number of other small molecules have
been shown to bind GAPDH and affect its higher order enzyme
structure, such as the antidiabetic compound demethylasterri-
quinone B1 and the saframycin class of natural products (Kim
et al., 2007; Xing et al., 2004). However, GAPDS can directly
bind to GAPDH and dramatically reduce cytoplasmic levels in
cancer cells, thus blocking any secondary moonlighting-associ-
ated functions of this enzyme in the cytoplasm (the saframycin
class of natural products increased nuclear localization of
GAPDH, but cytoplasmic levels were not significantly altered).
We also observed that GAPDH expression is less affected by
GAPDS treatment under hypoxia (Figure 3). It can be speculated
that this is due to the increased expression of GAPDH, which is
known to occur in the hypoxic environment (Xu et al., 2005).
An interesting finding from our results is the ability of GAPDS to
inhibit cancer cell invasion and reduce tubulin levels (Figures 3, 4,
and 5), which was not observed after treatment with the inhibitor
of GAPDH enzyme activity, 6-OHDA. This finding may be due to
the different mechanisms by which these small molecules bind
GAPDH. 6-OHDA oxidizes sulphydryl groups in GAPDH to block
enzyme activity (Hayes and Tipton, 2002). In contrast, GAPDS
prevents the tetramerization of GAPDH and segregates the
enzyme complex into monomers. Therefore, it can be specu-
lated that the ability of GAPDS to inhibit GAPDH tetramerization
is linked to the effects of this compound on cell motility and inva-
sion. This inhibition of GAPDH tetramerization reduces the cyto-
plasmic levels of GAPDH in colon cancer cells. As shown by our
analysis of GAPDH gene knockdown using siRNA (Figures 5D–
5G), reduced cytoplasmic levels of GAPDH produce a decrease
in a-tubulin expression. This may explain the effect of compound
GAPDS on cell invasion and motility. We also tested this hypoth-
esis by blocking GAPDH tetramerization via O-GlcNAcylation.
However, the two methods we used to induce O-GlcNAcylation5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1539
Figure 5. GAPDS Blocks Actin Polymerization and GAPDH Knockdown Decreases Tubulin Levels
(A) GAPDS-treated human HCT116 colon carcinoma cells fail to polymerize actin at the leading cell edge. Actin was visualized using fluorescent-
tagged phalloidin. Areas of actin polymerization in 6-OHDA-treated or untreated cells are indicated with white arrows. DAPI was used to visualize cell nuclei.
Scale bar, 10 mm.
(B) Treatment with 5 mM glucosamine, but not 50 mM PUGNAc, inhibited actin polymerization at the leading cell edge in HCT116 cells. Treatment with 5 mM
LY294002 did not affect actin polymerization, in accordance with its reported property as a PI3K signaling pathway inhibitor. Scale bar, 5 mm.
(C) GAPDS, but not 6-OHDA, shows synergy with Taxol to inhibit cancer cell viability. HCT116 cells were treated with compounds for 48 hr, as follows: 5 mM
GAPDS, 5 mM 6-OHDA, and 5 nM Taxol. Error bars indicate SD; *p < 0.05, compared to untreated cells.
(legend continued on next page)
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Figure 6. GAPDS Blocks Cancer Cell Migra-
tion In Vivo without Inducing Toxicity
(A) GAPDS treatment inhibited human HCT116
cancer cell dissemination in a human cancer
xenograft model. 6-OHDA treatment did not inhibit
cancer cell dissemination. Representative images
of xenografted larvae are shown. The bottom panel
is the fluorescence image to visualize labeled
cancer cells, and the top panel is the merged
fluorescence and differential interference contrast
images. Disseminated cancer cells are indicated by
blue arrows.
(B) Calculated invasion rate of cancer cells in xen-
ografted larvae treated with 6-OHDA (i) or GAPDS
(ii). Error bars indicate SD; *p < 0.05, compared to
untreated larvae.
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(Figures 4F–4H and 5B). Glucosamine treatment directly induces
the O-GlcNAcylation modification on cellular proteins and effec-
tively blocked cell invasion andmotility. However, treatment with
PUGNAc, which inducesO-GlcNAcylation of cellular proteins by
inhibiting O-GlcNAc-b-N-acetylglucosaminidase, did not affect
cell invasion and cell morphology. These conflicting results
may be due to the nonspecific effects of glucosamine and
PUGNAc treatment in cells. For example, PUGNAc treatment
has been shown to enhance cell invasion by increasing the
expression of E-cadherin (Jin et al., 2013). In contrast, com-
pound GAPDS has been shown to selectively bind to GAPDH
(Min et al., 2007). We have also shown that GAPDS treatment in-
duces GAPDH translocation to the cell nucleus (Figures 3D and
3E), which is linked to processes such as apoptosis and tumor-
igenesis (Colell et al., 2009; Ishitani et al., 1998). Thus, the
nuclear functions of GAPDH might contribute to the effects
observed after GAPDS treatment. Resolving this issue could
be an interesting approach for the further study of compound
GAPDS.
Drugs that target tubulin represent some of the most effective
anticancer medications (Jordan, 2002). Using siRNA gene
knockdown, we demonstrated that GAPDH is a regulator of
tubulin expression, validating the small molecule GAPDS as a
probe for characterizing the moonlighting functions of this
enzyme. GAPDH is a known virulence factor linked to cell inva-
sion into host tissues, and GAPDH colocalizes with microtubules
in cancer cells (Andrade et al., 2004; Seidler, 2013). Our results
show that GAPDH degradation affects cell cytoskeletal function
by reducing tubulin levels, which would inhibit cell invasion.
GAPDH can bind plasminogen on the cell surface and regulate(D) Tubulin levels in HCT116 cells treated with 120 pmol GAPDH or scrambled siRNA for 48 hr. Error bars ind
treated cells. Protein lysate (30 mg) was loaded for each treatment group.
(E) GAPDH expression is downregulated by GAPDH siRNA treatment in HCT116 cells. Cells were treated wi
*p < 0.05, compared to untreated cells.
(F) Representative western blot showing tubulin expression in siRNA-treated HCT116 cells.
(G) Representative western blot showing GAPDH expression in siRNA-treated HCT116 cells.
Chemistry & Biology 21, 1533–1545, November 20, 2014the cleavage of plasminogen into plasmin,
which initiates cell invasion (Seidler,
2013). GAPDS treatment may perturb the
interaction between GAPDH and plasmin-ogen to block cancer cell invasion. However, a previous study
has indicated that another glycolytic enzyme, enolase, is the
major regulator of plasminogen activation (Lo´pez-Alemany
et al., 2003), suggesting that the interaction of GAPDH with
tubulin is the mechanism linked to the anti-invasive effect of
GAPDS. This concept is supported by our data showing that
GAPDS has a synergistic effect with the anticancer drug, Taxol,
which also affects tubulin dynamics (Figure 5C). Thewestern blot
analysis in Figure 3A indicates that, at the 10 mM treatment con-
centration, there is still detectable a-tubulin expression in the
cancer cells. This suggests that the tubulin-binding drugs still
have some effectiveness in these cells.
A previous study by Nguyen et al. (2000) reported that
GAPDH localizes to pseudopodia in transformed kidney
epithelial cells and that motility was inhibited by blocking
glycolysis. However, our results showed that inhibition of
GAPDH glycolytic function using 6-OHDA did not affect cancer
cell motility (Figures 4A–4E). Instead, targeting GAPDH tetra-
merization using GAPDS blocked cell motility. It may be spec-
ulated that the disparity in these results is due to the different
methods used to inhibit glycolysis. The study by Nguyen
et al., blocked glycolysis using 2-deoxyglucose (which inhibits
phosphoglucoisomerase at the second step of glycolysis) or
oxamate (which is an inhibitory analog of pyruvate that
reduces the activity lactate dehydrogenase). Our study used
the small molecules GAPDS and 6-OHDA that specifically
target GAPDH to investigate the role of this enzyme in cell
motility. Thus, as a further study, it would be interesting to
test whether GAPDS and/or 6-OHDA inhibits pseudopodia for-
mation or motility in the transformed kidney epithelial cell sys-
tem used by Nguyen et al.icate SD; *p < 0.05, compared to scrambled siRNA-
th 120 pmol siRNA for 48 hr. Error bars indicate SD;
ª2014 Elsevier Ltd All rights reserved 1541
Chemistry & Biology
GAPDH Moonlighting Enhances Anticancer ActivityOur in vivo analysis showed that GAPDS is an effective anti-
cancer agent. This was achieved without inducing develop-
mental toxicity (Figure S5). This may be a notable result, because
there are concerns that targeting GAPDH is also cytotoxic for
normal cells (Krasnov et al., 2013). The zebrafish xenograft
model measures human cancer cell migration and invasion into
host tissues. The anti-invasive effect of GAPDS observed
in vitro was recapitulated in vivo. Moreover, the observed reduc-
tion of cancer cell migration (approximately 50%) compares
favorably with previous studies of well-known anticancer drugs
in this model system, such as paclitaxel and 17-DMAG (Jung
et al., 2012). Our mammalian analysis of GAPDS bioactivity uti-
lized the syngeneic mouse tumor model (Figure S6). This model
is valuable for testing potential antitumorigenesis agents (Darro
et al., 2005). Immune-deficient mouse xenograft models lack
lymphocytes, which are a component of tumor microenviron-
ment. In syngeneic models, tumorigenesis occurs in the mouse
strain in which the tumor originated and, in these immunocom-
petent hosts, the tumors grow relatively fast (Teicher, 2006).
Our data showed that GAPDS is effective at inhibiting tumorigen-
esis. The GAPDH enzyme inhibitor 6-OHDA also reduced tumor-
genesis in this mouse model. However, we observed that
6-OHDA-treated mice had reduced spleen weight. This may
be associated with immunological dysregulation related to
6-ODHA treatment (Warrell et al., 2003). At the early stage of tu-
mor formation, in-vivo-based imaging indicated that GAPDS is
more effective than 6-OHDA. However, at the time of sacrifice,
tumors dissected from GAPDS- or 6-OHDA-treated mice were
of a similar size (Figure S6). We speculate that GAPDS is more
effective at inhibiting the early stages of tumorigenesis in this
model system. However, because this model produces relatively
aggressive tumor growth, established tumors grow rapidly and
‘‘catch up’’ with those observed in 6-OHDA-treated mice, which
can become restricted by physical constraints such as hypoxia.
Thus, it would be interesting to compare GAPDS and 6-OHDA in
additional mammalian models of tumorigenesis, such as the
orthotopic xenograft model (Rajput et al., 2008).
The ability of GAPDS to modulate GAPDH secondary func-
tions is significant because mitochondrial respiration remains
effective in cancer cells, even though glycolysis is elevated (Kop-
penol et al., 2011). This suggests that inhibiting only the enzyme
function of glycolytic enzymes may be inefficient for producing
anticancer activity. This approach is supported by a report that
the glycolytic enzyme, glucose-6-phosphate isomerase, retains
its function as an autocrine cell motility factor, even when the
enzyme active site is mutated (Tsutsumi et al., 2003).
Compound GAPDS was initially identified as an antidiabetic
agent (Min et al., 2007). It has previously been demonstrated
that some antidiabetic drugs, such as metformin, also possess
anticancer activity (Gallagher and LeRoith, 2011). We previously
reported that a smallmolecule inhibitor of enolasealsopossesses
both antidiabetic and anticancer activity (Jung et al., 2013). We
believe that our data presented herein support the further devel-
opment of GAPDS as an anticancer drug. GAPDS may offer a
unique opportunity for further investigation of the role of GAPDH
in carcinogenesis. For example, it has recently been shown that
GAPDH can bind active protein kinase B (Akt), which induces
overexpression of the antiapoptosis factor, Bcl-xL and escape
from caspase-independent cell death (Jacquin et al., 2013). It1542 Chemistry & Biology 21, 1533–1545, November 20, 2014 ª2014would be interesting to test if GAPDS perturbs this binding to
Akt and the possible consequences on cell survival.
Overall, given the recent awareness that glycolytic enzymes
possess multiple moonlighting functions in cells, our results indi-
cate that small molecule screening systems may be developed
that detect the disruption of moonlighting functions in cancer
drug targets. This could lead to the discovery of potent anti-
cancer agents.
SIGNIFICANCE
The glycolytic enzyme GAPDH has been shown to carry
out numerous moonlighting functions that are linked to
carcinogenesis. The triazine compound GAPDH segregator
(GAPDS) prevents tetramer formation by GAPDH. Com-
pound GAPDS was previously described as a stimulator of
insulin signaling in Caenorhabditis elegans. In this study,
we show that chemical targeting of GAPDH tetramerization
by GAPDS produces anticancer activity. Developing tumors
create a hypoxic environment, which can reduce the effec-
tiveness of anticancer drugs and favor the survival of cancer
stem cells. Our results show that, compared to 6-OHDA, a
GAPDH enzyme inhibitor that does not necessarily affect
its quaternary structure, GAPDS is more effective at killing
cancer cells under both normoxia and hypoxia. In addition,
we discovered that GAPDS treatment blocks cell invasion
and migration. This was not observed after treatment with
6-OHDA. GAPDS treatment was shown to reduce cyto-
plasmic levels of GAPDH and tubulin. A link between GAPDH
levels and tubulin expression was confirmed using siRNA-
mediated knockdown of GAPDH expression. The potent
effect of GAPDS on cancer cell invasion was confirmed in
an animal model of metastasis. Thus, our study shows that
blocking GAPDH tetramerization reduces cytoplasmic
levels of this enzyme, which also reduces tubulin expression
and blocks the invasion of cancer cells in vivo. Overall, this
study establishes compound GAPDS as an attractive candi-
date for anticancer drug development.
EXPERIMENTAL PROCEDURES
The following procedures can be found in the Supplemental Information: flow
cytometry, western blotting analysis, preparation of nuclear extracts, and
mouse syngeneic model of tumorigenesis.
Reagents
GAPDS was synthesized by Y.-T.C. at the National University of Singapore.
Glucosamine, 6-OHDA, and iodoacetamide were purchased from Sigma-
Aldrich. Deferoxamine mesylate was purchased from BioVision. We pur-
chased 2,20-dipyridyl and PUGNAc from Santa Cruz Biotechnology. Texas
Red-X phalloidin and 1,10-dioctadecyl-3,3,30,30-tetramethyl-indocarbocya-
nine perchlorate (DiI) was purchased from Invitrogen. Antibodies for actin
(sc-1615), enolase (sc-271384), GAPDH (sc-48166), a-tubulin (sc-53646),
full-length caspase-9 (sc-7885), and laminin (sc-6018) were purchased from
Santa Cruz Biotechnology. Antibodies for cleaved PARP (#9541L), full-length
PARP (#46D11), and cleaved caspase-9 (#9501S) were purchased from Cell
Signaling.
Cell Culture
HCT116 human colon carcinoma cells and HeLa human cervical carcinoma
cells were cultured in 10% fetal bovine serum (FBS) and 1% P/S (53 103 units
per milliliter of penicillin and 5 mg/ml streptomycin) supplemented Dulbecco’sElsevier Ltd All rights reserved
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MD-231 human breast adenocarcinoma cells, and CT26 murine colon carci-
noma cells were cultured in RPMI medium supplemented with 10% FBS and
1% P/S.
Hypoxia was induced in using 150 mM of 0.22 mm filtered cobalt chloride
treatment, and the culture media volume was reduced by 50%, as previously
described (Piret et al., 2002). The compound of interest was added 4 hr after
the induction of hypoxia. The hypoxia mimetic deferoxamine mesylate was
used to induce hypoxia in HCT116 cells by 500 mM treatment for 16 hr, as pre-
viously described for this cell line (Yang et al., 2009). We used 2,20-dipyridyl to
induce hypoxia by 50 mM treatment for 18 hr, as previously described (Kuphal
et al., 2013).
Cell Viability and Cell Death Assays
Cell viability was measured using the tetrazolium dye methylthiotetrazole
(MTT) assay (Mosmann, 1983). Cells were seeded in hexaplicate in a 96-well
plate at a density of 5 3 103 cells per well. The compound of interest was
added and, after 48 hr incubation, the medium was changed to MTT solution
(0.5 mg/ml, final concentration) and the plate was incubated in a 37C 5%CO2
incubator. After 160min incubation, 80 ml of DMSOwas added. Optical density
in each well was measured at 570 nm with a microplate reader (VersaMax).
Cell deathwas detected using the trypan blue exclusion assay, as previously
described (Jung et al., 2013). Cells were prepared in a six-well plate at a den-
sity of 2 3 105 cells per well and treated with the compound of interest. After
48 hr compound treatment, cells were harvested by trypsinization and sus-
pended in 1 ml of PBS. A 100 ml aliquot of cells was taken and stained for
5 min with an equal volume of 0.4% trypan blue. Numbers of trypan-blue-
positive (dead) cells were counted using a hemocytometer.
GAPDH Activity Assay
Activity was measured using the KDalert GAPDH Assay Kit (Invitrogen),
following the manufacturer’s instructions. Cells were seeded in a 96-well plate
at a density of 1,000 cells per well. The compound of interest was added 24 hr
later. GAPDH activity was measured after 24 hr compound incubation using
the fluorometric method (lexcitation = 560 nm; lemission = 590 nm; SpectraMax
GeminiEM microplate reader). We used 5 ml cell lysate for the assay.
Quantitation of Cellular ATP Level
Cellular ATP levels were measured using the StayBrite luciferase-based assay
(BioVision), following themanufacturer’s instructions. For the assay, cells were
seeded in 96-well plates at a density of 1,000 cells per well. At 24 hr later,
compounds of interest were added directly to cells. Cells were cultured with
compound for 24 hr. Luminescence was measured using a multifunction
microplate reader (SpectraMax GeminiEM microplate reader).
RT-PCR
Total RNA was isolated using the TRI-Solution (Bio Science Technology) and
quantified with the NanoDrop 2000 spectrophotometer (Thermo Fisher Scien-
tific) at 240/260 nm. RNA (1 mg) was reverse transcripted into complementary
DNA using the AccuPower RT PreMix (Bioneer) following the manufacturer’s
instructions. GAPDH and cyclophilin were amplified using the AccuPower
PCR PreMix (Bioneer) with the following conditions: melting at 94C for
1 min, annealing 58.2C for 1 min, and extension at 72C for 30 s for 30 cycles.
Primer sequences for the genes are as follows: (1) GAPDH: forward 50-TGAT
GACATCAAGAAGGTGAAG-30 and reverse 50-TCCTTGGAGGCCATGTA
GGCCAT-30; and (2) cyclophilin: forward 50-GGCAAATGCTGGACCCAACA
CAA-30 and reverse 50-CTAGGCATGGGAGGGAACAAGGA-30.
Invasion Assay
To evaluate invasive activity, we used a modified transwell invasion assay
(Youngs et al., 1997). Using 24-transwell plates (Corning), the inserts contain-
ing 8-mm-pore filters were coated with collagen type I (45 mg/30 ml per well) for
the invasion assay. Briefly, carcinoma-associated fibroblasts (23 104 cells per
well) were seeded in the bottom wells for inducing cancer cell invasion.
Twenty-four hours later, cancer cells at a density of 1 3 105 cells per well
were placed in the upper transwell chambers with porous filters. The cancer
cells that penetrated the filter were fixed and stained with 0.25% crystal violet.
Cell invasion was quantified by counting the invaded cells, which wereChemistry & Biology 21, 1533–154counted in five separate microscopic fields (1003). Mean values per filter
(±SD) were calculated from three replicate filters.
Wound Healing Assay
The wound healing assay was carried out as previously described (Huang
et al., 2006). Briefly, cells were seeded onto six-well plates and allowed to
adhere overnight (achieving >90% confluence). The monolayer was wounded
with a 200 ml plastic pipette tip. Cells were washed once, and fresh culture
medium was added with or without the compound of interest. The cells were
allowed to invade the wound and counted by light microscopy 12 hr later.
The rate of wound healing was quantified bymeasuring the width of the wound
at five different sites every 24 hr using light microscopy (CKX41, Olympus) and
iSolution Lite 9.1 image capture software.
Assessment of Cell Morphology: Actin Visualization
Cells were seeded on glass coverslips for compound treatment. To visualize
actin, cells were washed twice with PBS and fixed with 3.7% formaldehyde
in PBS for 10 min. Cells were then washed two more times with PBS, and
the coverslips were then placed in a glass petri dish containing 0.1% Triton
X-100 in PBS for permeabilization. Cells were then washed two more times
with PBS, and a blocking step was carried out by incubation with 1% BSA in
PBS for 1 hr. Coverslips were then incubated with Texas Red-X phalloidin
(5 ml methanolic stock solution in 200 ml PBS) for 20 min at room temperature.
Coverslips were washed two more times with PBS and mounted with Fluoro-
mount AqueousMountingMedium (Sigma-Aldrich). Cells were imaged by fluo-
rescence microscopy (Leica DMI3000 B).
siRNA-Mediated Gene Silencing
siRNA-mediated knockdown of GAPDH expression was assessed using the
KDalert GAPDH Assay Kit (Invitrogen), which has been designed to facilitate
identification of optimal siRNA delivery conditions by assessment of GAPDH
expression. In accordance with the kit manufacturer’s guidelines, HCT116
cells were seeded in 96-well plates at a cell density of 104 cells per well.
Twenty-four hours after seeding, cells were transfected with 120 pmol of
siRNA, following themanufacturer’s protocol provided by Santa Cruz Biotech-
nology (reagent volumes were scaled down from the 6-well plate format to the
96-well plate format required for the GAPDH assay). Transfected cells were
used for the GAPDH assay at 48 hr posttransfection.
Zebrafish Human Cancer Cell Xenograft Model
Zebrafish were maintained by following standard procedures (Nusslein-Vol-
hard and Dahm, 2002). Care and treatment of zebrafish were conducted in
accordance with guidelines established by the Animal Care and Use Commit-
tees of the Gwangju Institute of Science and Technology, Republic of Korea.
The toxicity analysis is carried out in developing zebrafish larvae, which
show enhanced sensitivity to chemotoxic agents compared to adults. Zebra-
fish larvae can be tested in the 96-well plate format and are transparent, which
means developing organ systems can be imaged by light microscopy. In
accordance with previous studies of toxicological analysis (Hallare et al.,
2004; Peterson et al., 2000; Sipes et al., 2011), the following developmental
parameters were analyzed during embryogenesis: abnormal somite formation,
tail detachment, failure to develop otoliths (ears) or eyes, defective heart devel-
opment, abnormal blood circulation, delayed hatching, skeletal deformities,
and the failure to swim.
For the human cancer xenograft model, zebrafish embryos were obtained
using standard mating conditions and staged for cell xenoplantation at 48 hr
postfertilization. Twenty embryos were used for each treatment group. After
staining of cancer cells, embryos were dechorionized using microforceps
and anesthetized with 0.0016% tricaine and positioned on their right side on
a wet 1.0% agarose pad. Tumor cells were detached from the culture dishes
using 0.05% trypsin-EDTA and washed twice with PBS at room temperature.
Cells were stained with 2 mg/ml DiI diluted in PBS and washed four times: once
with FBS, twice with PBS, and then once with 10% FBS diluted in PBS. Cells
were kept on ice before injection. Cancer cells were counted by microscopy,
suspended in 10% FBS, and injected into the center of the yolk sac using an
injector (PV820 pneumatic picopump, World Precision Instruments) equipped
with borosilicate glass capillaries. Injected embryos were transferred to a 96-
well plate (one embryo per well) containing the drug of interest diluted in 200 ml5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1543
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GAPDH Moonlighting Enhances Anticancer ActivityE3 medium (without methylene blue). The number of embryos exhibiting can-
cer cell dissemination from the injection site was counted by upright fluores-
cence microscopy (Leica DM2500 Microscope). Representative pictures
were also captured using upright microscopy.
Statistical Analysis
Statistical significance was determined using the Student’s t test. A p value <
0.05 was deemed to be significant. Unless otherwise stated, all data shown are
representative of three experimental repeats.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2014.08.017.
AUTHOR CONTRIBUTIONS
D.-W.J. and W.-H.K. designed experiments and carried out the cell-based
tests of GAPDS, western analyses, RT-PCR, and the mouse tumorigenesis
study; S.S. carried out the cell-based tests, siRNA analysis, and zebrafish
xenograft study; E.O. carried out the zebrafish toxicology test; S.-H.Y. de-
signed experiments; H.-H.H. and Y.-T.C. synthesized GAPDS and provided
research advice; D.R.W. designed experiments and wrote the manuscript.
ACKNOWLEDGMENTS
This work was supported by a grant from the National Research Foundation
(NRF) and funded by the Korean Government (MEST Basic Science Research
Program grant NRF-2012R1A1B5000462 to D.-W.J.) and a grant (HI12C0275)
from the Korean Health Technology R&D Project, Ministry of Health and
Welfare, Republic of Korea. This work was also supported by the Bioimaging
Center, Gwangju Institute of Science and Technology.
Received: April 30, 2014
Revised: August 27, 2014
Accepted: August 28, 2014
Published: October 9, 2014
REFERENCES
Andrade, J., Pearce, S.T., Zhao, H., and Barroso, M. (2004). Interactions
among p22, glyceraldehyde-3-phosphate dehydrogenase and microtubules.
Biochem. J. 384, 327–336.
Bagley, R.G. (Ed.). (2010). The Tumor Microenvironment (Cancer Drug
Discovery and Development). (New York: Springer).
Champattanachai, V., Marchase, R.B., and Chatham, J.C. (2007).
Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion
injury via increased protein-associated O-GlcNAc. Am. J. Physiol. Cell
Physiol. 292, C178–C187.
Colell, A., Green, D.R., and Ricci, J.E. (2009). Novel roles for GAPDH in cell
death and carcinogenesis. Cell Death Differ. 16, 1573–1581.
Cragg, G.M. (1998). Paclitaxel (Taxol): a success story with valuable lessons
for natural product drug discovery and development. Med. Res. Rev. 18,
315–331.
Dai, R.P., Yu, F.X., Goh, S.R., Chng, H.W., Tan, Y.L., Fu, J.L., Zheng, L., and
Luo, Y. (2008). Histone 2B (H2B) expression is confined to a proper NAD+/
NADH redox status. J. Biol. Chem. 283, 26894–26901.
Darro, F., Decaestecker, C., Gaussin, J.F., Mortier, S., Van Ginckel, R., and
Kiss, R. (2005). Are syngeneic mouse tumor models still valuable experi-
mental models in the field of anti-cancer drug discovery? Int. J. Oncol. 27,
607–616.
Eguchi, Y., Shimizu, S., and Tsujimoto, Y. (1997). Intracellular ATP levels
determine cell death fate by apoptosis or necrosis. Cancer Res. 57, 1835–
1840.1544 Chemistry & Biology 21, 1533–1545, November 20, 2014 ª2014Ferguson, H.A., Marietta, P.M., and Van Den Berg, C.L. (2003). UV-induced
apoptosis is mediated independent of caspase-9 in MCF-7 cells: a model
for cytochrome c resistance. J. Biol. Chem. 278, 45793–45800.
Fuchs, J., Podda, M., and Packer, L. (2004). Redox-Genome Interactions in
Health and Disease. (New York: Marcel Dekker).
Gallagher, E.J., and LeRoith, D. (2011). Diabetes, cancer, and metformin: con-
nections of metabolism and cell proliferation. Ann. N Y Acad. Sci. 1243, 54–68.
Guo, C., Liu, S., and Sun, M.Z. (2013). Novel insight into the role of GAPDH
playing in tumor. Clin. Transl. Oncol. 15, 167–172.
Hallare, A.V., Ko¨hler, H.R., and Triebskorn, R. (2004). Developmental toxicity
and stress protein responses in zebrafish embryos after exposure to diclofe-
nac and its solvent, DMSO. Chemosphere 56, 659–666.
Haltiwanger, R.S., Grove, K., and Philipsberg, G.A. (1998). Modulation of
O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins
in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor
O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate.
J. Biol. Chem. 273, 3611–3617.
Hayes, J.P., and Tipton, K.F. (2002). Interactions of the neurotoxin 6-hydroxy-
dopamine with glyceraldehyde-3-phosphate dehydrogenase. Toxicol. Lett.
128, 197–206.
Huang, M.C., Chen, H.Y., Huang, H.C., Huang, J., Liang, J.T., Shen, T.L., Lin,
N.Y., Ho, C.C., Cho, I.M., and Hsu, S.M. (2006). C2GnT-M is downregulated in
colorectal cancer and its re-expression causes growth inhibition of colon can-
cer cells. Oncogene 25, 3267–3276.
Ishitani, R., Tanaka, M., Sunaga, K., Katsube, N., and Chuang, D.M. (1998).
Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydro-
genase in cultured cerebellar neurons undergoing apoptosis. Mol. Pharmacol.
53, 701–707.
Jacquin, M.A., Chiche, J., Zunino, B., Be´ne´teau, M., Meynet, O., Pradelli, L.A.,
Marchetti, S., Cornille, A., Carles, M., and Ricci, J.E. (2013). GAPDH binds to
active Akt, leading to Bcl-xL increase and escape from caspase-independent
cell death. Cell Death Differ. 20, 1043–1054.
Jeffery, C.J. (2009). Moonlighting proteins—an update. Mol. Biosyst. 5,
345–350.
Jin, F.Z., Yu, C., Zhao, D.Z., Wu, M.J., and Yang, Z. (2013). A correlation be-
tween altered O-GlcNAcylation, migration and with changes in E-cadherin
levels in ovarian cancer cells. Exp. Cell Res. 319, 1482–1490.
Jordan, M.A. (2002). Mechanism of action of antitumor drugs that interact with
microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2, 1–17.
Jung, D.W., Oh, E.S., Park, S.H., Chang, Y.T., Kim, C.H., Choi, S.Y., and
Williams, D.R. (2012). A novel zebrafish human tumor xenograft model vali-
dated for anti-cancer drug screening. Mol. Biosyst. 8, 1930–1939.
Jung, D.W., Kim, W.H., Park, S.H., Lee, J., Kim, J., Su, D., Ha, H.H., Chang,
Y.T., and Williams, D.R. (2013). A unique small molecule inhibitor of enolase
clarifies its role in fundamental biological processes. ACS Chem. Biol. 8,
1271–1282.
Kim, J.W., and Dang, C.V. (2005). Multifaceted roles of glycolytic enzymes.
Trends Biochem. Sci. 30, 142–150.
Kim, H., Deng, L., Xiong, X., Hunter, W.D., Long, M.C., and Pirrung, M.C.
(2007). Glyceraldehyde 3-phosphate dehydrogenase is a cellular target of
the insulin mimic demethylasterriquinone B1. J. Med. Chem. 50, 3423–3426.
Konantz, M., Balci, T.B., Hartwig, U.F., Dellaire, G., Andre´, M.C., Berman, J.N.,
and Lengerke, C. (2012). Zebrafish xenografts as a tool for in vivo studies on
human cancer. Ann. N Y Acad. Sci. 1266, 124–137.
Koppenol, W.H., Bounds, P.L., and Dang, C.V. (2011). Otto Warburg’s contri-
butions to current concepts of cancer metabolism. Nat. Rev. Cancer 11,
325–337.
Krasnov, G.S., Dmitriev, A.A., Snezhkina, A.V., and Kudryavtseva, A.V. (2013).
Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydroge-
nase as a therapeutic target. Expert Opin. Ther. Targets 17, 681–693.
Kuphal, S., Wallner, S., and Bosserhoff, A.K. (2013). Impact of LIF (leukemia
inhibitory factor) expression in malignant melanoma. Exp. Mol. Pathol. 95,
156–165.Elsevier Ltd All rights reserved
Chemistry & Biology
GAPDH Moonlighting Enhances Anticancer ActivityLee, J., Jung, D.W., Kim, W.H., Um, J.I., Yim, S.H., Oh, W.K., and Williams,
D.R. (2013). Development of a highly visual, simple, and rapid test for the dis-
covery of novel insulin mimetics in living vertebrates. ACSChem. Biol. 8, 1803–
1814.
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad, M., Alnemri, E.S.,
andWang, X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/
caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479–489.
Lo´pez-Alemany, R., Longstaff, C., Hawley, S., Mirshahi, M., Fa´bregas, P.,
Jardı´, M., Merton, E., Miles, L.A., and Fe´lez, J. (2003). Inhibition of cell surface
mediated plasminogen activation by a monoclonal antibody against alpha-
Enolase. Am. J. Hematol. 72, 234–242.
Martens, L.K., Kirschner, K.M., Warnecke, C., and Scholz, H. (2007). Hypoxia-
inducible factor-1 (HIF-1) is a transcriptional activator of the TrkB neurotrophin
receptor gene. J. Biol. Chem. 282, 14379–14388.
Min, J., Kyung Kim, Y., Cipriani, P.G., Kang, M., Khersonsky, S.M., Walsh,
D.P., Lee, J.Y., Niessen, S., Yates, J.R., 3rd, Gunsalus, K., et al. (2007).
Forward chemical genetic approach identifies new role for GAPDH in insulin
signaling. Nat. Chem. Biol. 3, 55–59.
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65,
55–63.
Nguyen, T.N., Wang, H.J., Zalzal, S., Nanci, A., and Nabi, I.R. (2000).
Purification and characterization of beta-actin-rich tumor cell pseudopodia:
role of glycolysis. Exp. Cell Res. 258, 171–183.
Nusslein-Volhard, C., and Dahm, R., eds. (2002). Zebrafish (The Practical
Approach Series) (New York: Oxford University Press).
Park, J., Han, D., Kim, K., Kang, Y., and Kim, Y. (2009). O-GlcNAcylation dis-
rupts glyceraldehyde-3-phosphate dehydrogenase homo-tetramer formation
andmediates its nuclear translocation. Biochim. Biophys. Acta 1794, 254–262.
Pelicano, H., Martin, D.S., Xu, R.H., and Huang, P. (2006). Glycolysis inhibition
for anticancer treatment. Oncogene 25, 4633–4646.
Peterson, R.T., Link, B.A., Dowling, J.E., and Schreiber, S.L. (2000). Small
molecule developmental screens reveal the logic and timing of vertebrate
development. Proc. Natl. Acad. Sci. USA 97, 12965–12969.
Piret, J.P., Mottet, D., Raes, M., and Michiels, C. (2002). CoCl2, a chemical
inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death
in hepatoma cell line HepG2. Ann. N Y Acad. Sci. 973, 443–447.
Rajput, A., Dominguez San Martin, I., Rose, R., Beko, A., Levea, C., Sharratt,
E., Mazurchuk, R., Hoffman, R.M., Brattain, M.G., and Wang, J. (2008).
Characterization of HCT116 human colon cancer cells in an orthotopic model.
J. Surg. Res. 147, 276–281.
Schmidt, M.M., and Dringen, R. (2009). Differential effects of iodoacetamide
and iodoacetate on glycolysis and glutathione metabolism of cultured astro-
cytes. Front. Neuroenergetics 1, 1.
Seidler, N.W. (2013). GAPDH, as a virulence factor. Adv. Exp. Med. Biol. 985,
149–178.
Sipes, N.S., Padilla, S., and Knudsen, T.B. (2011). Zebrafish: as an integrative
model for twenty-first century toxicity testing. Birth Defects Res. C Embryo
Today 93, 256–267.Chemistry & Biology 21, 1533–154Spinella, F., Rosano`, L., Del Duca, M., Di Castro, V., Nicotra, M.R., Natali, P.G.,
and Bagnato, A. (2010). Endothelin-1 inhibits prolyl hydroxylase domain 2 to
activate hypoxia-inducible factor-1alpha in melanoma cells. PLoS ONE 5,
e11241.
Subramanian, A., and Miller, D.M. (2000). Structural analysis of alpha-enolase.
Mapping the functional domains involved in down-regulation of the c-myc pro-
tooncogene. J. Biol. Chem. 275, 5958–5965.
Teicher, B.A. (2006). Tumor models for efficacy determination. Mol. Cancer
Ther. 5, 2435–2443.
Tewari, M., Quan, L.T., O’Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R.,
Poirier, G.G., Salvesen, G.S., and Dixit, V.M. (1995). Yama/CPP32 beta, a
mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves
the death substrate poly(ADP-ribose) polymerase. Cell 81, 801–809.
Tristan, C., Shahani, N., Sedlak, T.W., and Sawa, A. (2011). The diverse func-
tions of GAPDH: views from different subcellular compartments. Cell. Signal.
23, 317–323.
Tsutsumi, S., Gupta, S.K., Hogan, V., Tanaka, N., Nakamura, K.T., Nabi, I.R.,
and Raz, A. (2003). The enzymatic activity of phosphoglucose isomerase is
not required for its cytokine function. FEBS Lett. 534, 49–53.
Warburg, O., Wind, F., and Negelein, E. (1927). The metabolism of tumors in
the body. J. Gen. Physiol. 8, 519–530.
Warrell, D.A., Cox, T.M., Firth, J.D., and Benz, E.J., Jr. (2003). Oxford Textbook
of Medicine, Fourth Edition. (New York: Oxford University Press).
Wu, D., and Yotnda, P. (2011). Induction and testing of hypoxia in cell culture.
J. Vis. Exp. (54), 2899.
Xing, C., LaPorte, J.R., Barbay, J.K., and Myers, A.G. (2004). Identification of
GAPDH as a protein target of the saframycin antiproliferative agents. Proc.
Natl. Acad. Sci. USA 101, 5862–5866.
Xu, R.H., Pelicano, H., Zhou, Y., Carew, J.S., Feng, L., Bhalla, K.N., Keating,
M.J., and Huang, P. (2005). Inhibition of glycolysis in cancer cells: a novel strat-
egy to overcome drug resistance associated with mitochondrial respiratory
defect and hypoxia. Cancer Res. 65, 613–621.
Yang, J., Ahmed, A., Poon, E., Perusinghe, N., de Haven Brandon, A., Box, G.,
Valenti, M., Eccles, S., Rouschop, K., Wouters, B., and Ashcroft, M. (2009).
Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and
vascular endothelial growth factor expression in vivo and leads to tumor cell
apoptosis in normoxia and hypoxia. Mol. Cell. Biol. 29, 2243–2253.
Yeung, T.M., Gandhi, S.C., Wilding, J.L., Muschel, R., and Bodmer, W.F.
(2010). Cancer stem cells from colorectal cancer-derived cell lines. Proc.
Natl. Acad. Sci. USA 107, 3722–3727.
Youngs, S.J., Ali, S.A., Taub, D.D., and Rees, R.C. (1997). Chemokines induce
migrational responses in human breast carcinoma cell lines. Int. J. Cancer 71,
257–266.
Yuan, Y., Hilliard, G., Ferguson, T., andMillhorn, D.E. (2003). Cobalt inhibits the
interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau
protein by direct binding to hypoxia-inducible factor-alpha. J. Biol. Chem.
278, 15911–15916.
Zhang, X.D., Deslandes, E., Villedieu, M., Poulain, L., Duval, M., Gauduchon,
P., Schwartz, L., and Icard, P. (2006). Effect of 2-deoxy-D-glucose on various
malignant cell lines in vitro. Anticancer Res. 26 (5A), 3561–3566.5, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1545
